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Summary 
Periodontitis is an inflammatory infectious disease that destroys the tooth-supporting 
tissues. It is caused by multi-species subgingival biofilms that colonize the tooth surface. 
Porphyromonas gingivalis, Treponema denticola and Tannerella forsythia (i.e. “red 
complex” bacteria) are characteristic subgingival biofilm species. The Triggering 
Receptor Expressed on Myeloid cells 1 (TREM-1) is a cell surface receptor of the 
immunoglobulin super-family, with a role in the amplification of pro-inflammatory 
cytokine production during infection. This study aimed to investigate TREM-1 mRNA 
expression in gingival tissues from patients with chronic periodontitis, generalised 
aggressive periodontitis and healthy subjects, and its correlation with the levels of 
periodontal pathogens in the tissue. A further aim was to investigate the regulation of 
TREM-1 in human monocytic cells (MM6) challenged with an in vitro subgingival biofilm 
model. Gingival tissue TREM-1 expression was increased in both chronic and 
aggressive periodontitis, compared to health, and correlated with the levels of the “red 
complex” species in the tissue. No significant differences were detected between the two 
forms of periodontitis. Biofilm-challenged MM6 cells exhibited higher TREM-1 
expression and secretion compared to controls, irrespective of the presence of the “red 
complex”. Engagement or inhibition of TREM-1 affected the capacity of the biofilms to 
stimulate Interleukin (IL)-1β, but not IL-8, secretion by the cells. In conclusion, this study 
reveals that TREM-1 tissue expression is enhanced in periodontal disease, and 
correlates with the level of periodontal pathogens. It also provides a mechanistic insight 
into the regulation of TREM-1 expression and the associated IL-1β production, in 
biofilm-challenged monocytes. 
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Introduction 
Periodontitis is an inflammatory oral disease affecting the tooth-supporting (periodontal) 
tissues, including the gingiva, periodontal ligament and alveolar bone, leading to their 
progressive destruction. The most common forms of periodontal disease are chronic and 
aggressive periodontitis [1, 2]. Both forms are caused by the inflammatory host reaction 
to the accumulation of bacterial biofilm at the gingival margin, as well as subgingivally in 
periodontal pockets. Chronic periodontitis leads to the progressive destruction of the 
tooth supporting structures at a slower rate, whereas aggressive periodontitis is 
characterized by a faster destruction, often progressing in exacerbations. 
The bacteria most commonly associated with chronic periodontitis are classified 
into the “red complex” species, namely Porphyromonas gingivalis, Tannerella forsythia 
and Treponema denticola, whereas Aggregatibacter actinomycetemcomitans is 
predominantly found in aggressive periodontitis [3, 4]. These Gram negative anaerobes 
reside in the subgingival biofilm and have been shown to not only colonise the 
periodontal pockets, but also adhere to, and subsequently invade, host cells and tissues 
[5-8]. 
Triggering Receptor Expressed on Myeloid cells 1 (TREM-1) is a transmembrane 
receptor of the immunoglobulin superfamily known to be expressed in monocytes and 
neutrophils [9], cells which are crucial regulators of the innate immune response against 
bacterial infection, including the establishment of subgingival biofilm microbiota in 
periodontitis. TREM-1 is considered to be an important regulator of the magnitude, 
rather than the initiation, of the immune response to bacterial challenge and the 
consequent production of pro-inflammatory cytokines [10]. It is highly produced and 
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released during systemic infections and postulated to play a role in systemic sepsis, as 
well as other inflammatory diseases [11-17]. 
Neutrophils and monocytes can be found in great numbers in the inflamed tissues 
around periodontal pockets and are contributing to periodontal tissue destruction by their 
immunoreactions against invading bacteria, or their secreted virulence factors [18]. 
TREM-1 may therefore play an important role in the regulation of the severity of host 
reactions that lead to periodontal tissue destruction. It has previously been shown that P. 
gingivalis, a member of the “red complex”, can stimulate the production of TREM-1 in 
monocytes and neutrophils, leading to an increased release of pro-inflammatory 
cytokines in vitro [19, 20]. It has also been demonstrated in clinical studies that the 
soluble form of TREM-1 (sTREM-1) can be found in increased amounts in the saliva and 
serum of patients with periodontitis, when compared to healthy individuals [21]. 
Furthermore it has been shown that the amount of sTREM-1 in gingival cervical fluid 
from sites affected by chronic or aggressive periodontitis is correlated with the presence 
of the “red complex” bacteria, as well as the clinical measurements of the disease [22]. It 
is not yet clear if these correlations of TREM-1 with clinical and microbiological 
parameters can also be found at the gene expression level, within the inflamed 
periodontal tissues. 
Hence, the aim of the present study was to assess the expression of TREM-1 at 
the mRNA level in gingival tissue from sites affected by chronic and aggressive 
periodontitis, as well as healthy sites, and to investigate its correlation with clinical 
periodontal measurements and the levels of the “red complex” bacteria and A. 
actinomycetemcomitans within these tissues. Furthermore, the in vitro branch of this 
study aimed to investigate the regulation of TREM-1 as an innate immune response of 
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monocytic cells, upon their challenge with culture supernatants from a multi-species 
subgingival biofilm model. The effect of inhibition or engagement of TREM-1 on the 
production of pro-inflammatory cytokines by these cells was also assessed. 
The hypothesis is that TREM-1 gene expression is increased in periodontal 
tissues affected by periodontitis and positively correlates with site-specific clinical and 
microbiological parameters. Furthermore, it is hypothesised that modulation of TREM-1 
affects the levels of pro-inflammatory cytokines produced by monocytes challenged with 
oral biofilm secreted products. 
 
Materials and Methods 
Study population and clinical examination 
Forty-five subjects recruited from November 2011 until March 2012 at the clinics of the 
Department of Periodontology, School of Dentistry, Ege University, Izmir, Turkey were 
included in this study. All participants gave their informed consent and the use of human 
participants met all requirements of Ege University Institutional Review board (ethics 
approval number: 11-12.1/11). The study population included cases diagnosed with 
chronic periodontitis (n=15), aggressive periodontitis (n=15) and non-periodontitis 
healthy controls (n=15). Diagnosis of the form of periodontitis was in accordance with 
the criteria of the 1999 International World Workshop for a Classification of Periodontal 
Disease and Conditions [1]. This study population comprises part of a population that 
has previously been analysed. Hence, more detailed information on recruitment 
diagnostic procedures can be found elsewhere [21, 22].  
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Collection of gingival tissue samples 
Gingival tissue samples, including both epithelium and connective tissue, were taken 
from the approximal sites of single-rooted teeth prior to non-surgical periodontal therapy 
in the instance of periodontally diseased subjects, and during tooth extractions for 
orthodontic reasons or crown-lengthening procedures in non-periodontitis subjects, as 
previously described [23]. One tissue sample from each subject was obtained and 
submerged immediately in a sterile tube containing RNAlater solution (Ambion Inc., 
Austin, TX, USA), stored at -80°C until further lab oratory analysis. 
Extraction of DNA and RNA from gingival tissue samples 
The total DNA and RNA were extracted from the gingival tissue samples using the 
AllPrep Mini Kit (QIAGEN), according to the manufacturer’s instructions. The obtained 
DNA was used for the determination of the bacterial levels in the tissue, whereas the 
RNA was used for the determination of TREM-1 gene expression in the tissue. The 
concentration of both nucleic acids was measured using a NanoDrop 1000 
spectophotometer. One µg of total RNA was further reverse transcribed into cDNA using 
0.5 µg oligodT primers (Promega). Prior to adding the reverse transcription mastermix 
the RNA and primers in 15µl of nuclease free water were heated to 70°C for 5min and 
then cooled to 6°C and centrifuged. The master mix contained 5 µl M-MLV RT buffer, 
1.25 µl of 10mM dNTPs, 1 µl M-MLV reverse transcriptase (all from Promega) and 3.75 
µl nuclease free water. For the reverse transcription reaction, the samples were heated 
at 40°C for 60 min, and then at 70°C for 15 min, an d were finally cooled down to 6°C. 
The resulting cDNA samples were stored at -20°C, un til further use. 
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Analysis of TREM-1 mRNA expression in gingival tissue samples by TaqMan 
quantitative real-time PCR (qPCR) 
Relative expression of human TREM-1, as well as of the housekeeping gene 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in the gingival tissue samples, 
were analysed by qPCR (TaqMan Gene Expression, Applied Biosystems). The Applied 
Biosystems assay IDs were for TREM-1 Hs00218624_m1 and for GAPDH 
Hs99999905_m1. The cDNA amplification and detection was performed in a real time 
PCR system (Step One Plus, Applied Biosystems) using TaqMan Gene Expression 
Master Mix (Applied Biosystems). Each reaction was carried out in a total volume of 16 
µl. Thereafter the relative expression of TREM-1 was calculated using the 2-∆CT method. 
Bacterial quantification by qPCR 
Quantification of the “red complex” bacteria (namely, T. forsythia, T. denticola, P. 
gingivalis) and A. actinomycetemcomitans was performed by qPCR, using species-
specific oligonucleotide primers targeting the 16S rRNA gene. The primers were 
designed and used as previously described in [24], and their sequences are provided in 
Table 1. DNA amplification and detection was performed in a real time PCR system 
(Step One Plus, Applied Biosystems), using SYBR Green Master Mix for the 
amplification reaction (Applied Biosystems). Each reaction was performed in a total 
volume of 12 µl, including the primers solution, mastermix and 50 ng of the total DNA 
extracted from the tissue samples. Standard curves generated from extracted DNA of 
known concentrations from pure cultures of all four species tested were used to 
calculate the estimated amount of bacteria in the tissue samples, as previously 
described in [22]. 
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Human monocytic cell culture 
The human monocytic cell line Mono Mac 6 (MM6) obtained from the German Collection 
of Microorganisms and Cell Cultures (Mascheroder, Braunschweig, Germany) was used 
in this study. Cells frozen in liquid nitrogen were defrosted quickly and transferred into 
complete medium containing 87% RPMI-glutamax, 10% fetal bovine serum, 1% 
nonessential amino acids, 1% sodium pyruvate, 0.02% fungizone solution (all from 
Gibco BRL Life Technologies, Paisley, UK), 1% penicillin/streptomycin solution and 
0.1% recombinant human insulin solution (both from Sigma-Aldrich, St. Louis, USA). To 
remove the cryoprotectant DMSO the cell suspension was centrifuged for 5 min at 1500 
rpm. The supernatant was removed, while the resulting cell pellet was re-suspended in 
freshly reconstituted complete media. For the experimentations, the cells were then 
counted using a haemocytometer and Trypan blue staining, and were seeded at a 
concentration of 106 cells/ml. 
Biofilm supernatants 
To challenge the cells, culture supernatants from a 10-species “subgingival” biofilm 
model were used, or its 7-species variant excluding the “red complex”, as described 
elsewhere [25-27]. In brief, these multi-species biofilms were grown on hydroxyapatite 
discs, in medium consisting of 60% of processed whole un-stimulated pooled saliva, 
30% modified fluid universal medium (mFUM) and 10 % heat inactivated human serum, 
under anaerobic conditions at 37 °C, for a total of  64.5 h. The 10 species composing the 
biofilm were Streptococcus oralis SK248 (OMZ 607), Streptococcus anginosus ATCC 
9895 (OMZ 871), Actinomyces oris (OMZ 745; formerly Actinomyces naeslundii), 
Fusobacterium nucleatum subsp. nucleatum OMZ 598, Veillonella dispar ATCC 17748T 
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(OMZ 493), Campylobacter rectus OMZ 698, Prevotella intermedia ATCC 25611T (OMZ 
278), Porphyromonas gingivalis ATCC 33277T (OMZ 925), Tannerella forsythia OMZ 
1047, and Treponema denticola ATCC 35405T (OMZ 661). This biofilm composition of 
10-species was designated as “BF”. The relative involvement of the “red complex” 
species was evaluated growing a biofilm variant whereby T. denticola, P. gingivalis and 
T. forsythia had been omitted form the composition (designated as “BF-RC”). After a 
total 64.5 h of incubation, at an advanced stage of biofilm maturation, the culture 
supernatants were collected, filtered and stored at -80°C. The bacterial protein 
concentration in these biofilm culture supernatants was determined by the BCA Protein 
Assay (Pierce), as previously described [25]. For the experiments, these biofilm 
supernatant preparations were diluted into the final cell culture medium in order to 
challenge the MM6 cells. 
Challenging MM6 cells with biofilm supernatants 
For the experiments, 250 µl of MM6 cell suspension (106 cells/ml) were cultured in 
complete media without antibiotics, in the presence or absence of the biofilm 
supernatants. In some experiments, prior to being challenged with the biofilm, the MM6 
cells were pre-treated either by engaging or inhibiting TREM-1 as described in the next 
sections. The cells were challenged for up-to 24 h with 100 µg/ml protein concentration 
of either biofilm supernatant (BF or BF-RC), while corresponding MM6 cultures in the 
absence of biofilm supernatant were used as controls. Upon completion the cells were 
pelleted by centrifugation (1500 rpm, 5 min), and 5 µl of protease inhibitor (ETDA-free 
Protease Inhibitor Cocktail Tablets, Roche) were added to the resulting culture 
supernatants. The supernatants were then processed for further analysis by ELISA, as 
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described in the next sections. The cell-pellets were washed in sterile PBS once, and 
stored at -20°C until further use. 
TREM-1 engagement 
To enhance the activity of the TREM-1 pathway in MM6 cells upon challenge with biofilm 
supernatants, TREM-1 was engaged by 10 µg/ml anti-human TREM-1 antigen affinity-
purified polyclonal goat IgG, whereas goat IgG was used as an isotype control (both 
from R&D Systems, Abington, UK). The culture plates were pre-coated with 100 µl of 
either IgG suspension and left overnight at +4°C. B efore use, they were placed at room 
temperature for 1 h, and the wells were washed with sterile PBS once. Thereafter, the 
cells were incubated for 24 h in these pre-coated wells, in the presence or absence of 
biofilm supernatants, and the samples harvested as described above. 
TREM-1 inhibition 
To reduce the activity of the TREM-1 pathway in MM6 cells upon challenge with biofilm 
supernatants, TREM-1 was inhibited by its synthetic antagonist LP17 (Pepscan Presto 
B.V., Lelystad, The Netherlands). For the experiments, LP17 was added to the cell 
suspension at a concentration of 100 ng/ml and then further incubated at 37°C for 20 
min. Thereafter, the cell suspension was centrifuged and the cells were re-suspended in 
complete medium in the absence of antibiotics, followed by further addition of LP17 (100 
ng/ml), in the presence or absence of biofilm supernatants for 6 h and 24 h, as 
described above. 
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Enzyme-linked immunosorbent assay (ELISA) 
Human Interleukin-1β (IL-1β), Interleukin-8 (IL-8) and TREM-1 ELISA kits (DuoSet, R&D 
Systems, Abington, UK) were used to determine the amounts of these molecules in the 
MM6 culture supernatants, following biofilm challenge, according to the manufacturer’s 
instructions. Upon completion of the experiments, the cell-free culture supernatants were 
transferred to 96-well ELISA plates and analysed spectophotometrically, using an 
EPOCH microplate reader (BioTek, Lucerne, Switzerland) by measuring the absorbance 
at 450nm and subtracting background readings at 570nm. Standard curves were 
calculated by four-parameter polynomial regression using rhIL-1β, rhIL-8 and rhsTREM-
1 standards provided in the ELISA kits, and the concentrations of these molecules in the 
experimental samples were calculated based on these curves. 
RNA isolation from MM6 cells 
To isolate total RNA from MM6 cells the RNeasy Mini Kit (Qiagen) was used. The cells 
were harvested from the culture and washed with sterile PBS. Thereafter, 350 µl of lysis 
buffer RLT, provided in the kit, were added to the cell pellet and the cells lysed by 
pipetting. Total RNA was then extracted and isolated, following the manufacturer’s 
protocol for purification of total RNA from animal cells. The concentration of the 
extracted total RNA was measured with a NanoDrop 1000 Spectrophotometer and the 
RNA samples stored at -20°C, until further use. 
Analysis of TREM-1 mRNA expression in MM6 cells by qPCR 
One µg of RNA isolated from MM6 cells was reverse transcribed to cDNA using the 
OligodT method, and the relative expression of human TREM-1 was then analysed by 
qPCR as described above, calibrated against the expression of the β2-microglobulin 
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(B2M) (Applied Biosystems Gene Expression Assay ID: Hs99999907_m1) that was 
used as internal housekeeping gene control.  
Cytotoxicity assay 
The potential cytotoxicity elicited by the two biofilm supernatants on the MM6 cultures 
was evaluated by measuring the extracellularly released cytosolic lactate 
dehydrogenase (LDH), using the CytoTox96® Non-Radioactive Cytotoxicity Assay 
(Promega), according to the manufacturer’s instructions. After completion of the 
experiments, the cell culture supernatants were collected, centrifuged at 1500 rpm for 5 
min, and transferred into an optically clear 96-well plate, followed by addition of reaction 
solution and incubated for 30 min in the dark. The reaction was then stopped and the 
absorbance was measured spectophotometrically at 490 nm in and EPOCH microplate 
reader (Biotek, Lucerne, Switzerland), subtracting background values from all samples. 
Statistical Analysis 
Clinical and microbiological findings were statistically analysed using the IBM SPSS 
Statistics program version 21 (International Business Machines Corporation, Armonk, 
USA). Mann-Whitney-U-tests were performed to calculate significance levels. To 
analyse correlations between TREM-1 expression and clinical and microbiological 
parameters, the Spearman's rank correlation coefficients were calculated. The data of 
the in vitro experiments were analysed by the GraphPad Prism software version 6.02 
(GraphPad Software, Inc., La Jolla, USA). Unpaired T-tests were used to calculate 
significance levels. 
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Results 
Clinical and microbiological findings 
Full mouth clinical measurements are provided in Table 2, whereas site-specific clinical 
parameters are provided in Table 3. Full mouth clinical parameters were significantly 
higher in cases of chronic and aggressive periodontitis compared to healthy controls 
(Table 2). Site specific clinical parameters were also significantly higher in both forms of 
periodontitis compared to healthy sites (p<0.0001) (Table 3). Matching the clinical 
measurements, the levels of all three “red complex” bacteria were significantly higher in 
chronic, as well as aggressive periodontitis, than in health. P. gingivalis numbers were 
increased by almost 3-log in chronic and aggressive periodontitis (p<0.0001) (Fig 1A). T. 
forsythia numbers were increased by ≥ 1-log in chronic (p< 0.0001) and aggressive 
periodontitis (p<0.01) (Fig. 1B). T. denticola numbers were increased by 1.7-log in 
chronic periodontitis and 1.5-log in aggressive periodontitis, compared to health (p < 
0.0001) (Fig. 1C). Nevertheless, A. actinomycetemcomitans numbers showed no 
significant increase in chronic periodontitis compared to health, whereas in aggressive 
periodontitis the numbers were significantly increased by a factor of 4.4-log (p<0.01) (Fig 
1D). Overall, with the exception of A. actinomycetemcomitans which was significantly 
increased in aggressive periodontitis when compared to chronic periodontitis (p=0.034), 
no other differences were observed between the two forms of periodontitis in terms of 
clinical parameters or bacterial numbers. 
TREM-1 mRNA expression in gingival biopsies 
TREM-1 relative mRNA expression in gingival biopsies from sites with chronic and 
aggressive periodontitis, as well as from healthy sites, was analysed by qPCR, using 
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GAPDH as an internal house-keeping gene control and the relative expression of 
TREM-1 calculated by the 2-∆CT method. TREM-1 expression was significantly increased 
in both forms of periodontitis when compared to healthy sites (p<0.05) (Fig. 2). In 
chronic periodontitis, TREM-1 expression was increased by 3-fold, whereas in 
aggressive periodontitis by 13-fold, compared to the healthy controls. Nevertheless, this 
difference between chronic and aggressive periodontitis did not prove to be significant. 
Correlations between site-specific clinical and microbiological findings and 
TREM-1 mRNA expression in gingival biopsies 
Spearman’s rank correlation coefficients were calculated for TREM-1 relative expression 
in gingival biopsies and site specific clinical measurements as well as microbiological 
findings (Table 4). The PD, CAL and PI did not show significant correlation with TREM-1 
expression. However, as a clinical indicator of inflammation, BOP demonstrated a 
significantly positive correlation with TREM-1 expression (r=0.363, p=0.014). Moreover, 
TREM-1 tissue expression showed a significant correlation with the numbers of all three 
“red complex” species (p<0.005), but not in the case of A. actinomycetemcomitans. 
Regulation of TREM-1 in MM6 cells in response to biofilm challenge 
The MM6 cells were challenged for 3 h with 100 µg/ml protein of biofilm culture 
supernatants, either BF or BF-RC. The sTREM-1 levels secreted in the cell culture were 
evaluated by ELISA, whereas TREM-1 mRNA expression was evaluated by qPCR. 
sTREM-1 secretion was significantly induced in both biofilm-challenged groups, whereas 
this was not detected in the control group that was not challenged by biofilm 
supernatants (Fig. 3A). The highest sTREM-1 secreted levels were observed in MM6 
cells challenged with BF, which included the “red complex”, whereas BF-RC, lacking 
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these species, resulted in 2.2-fold lower levels than BF. However, the difference 
between the two groups was at the border of being significant (p=0.055). With regards to 
TREM-1 mRNA expression (Fig. 3B), this was significantly (p=0.0256) higher by 1.35-
fold in cells challenged with BF, compared to BF-RC. Both biofilm-challenged groups 
displayed significantly higher TREM-1 expression than the controls (p=0.0033 and 
p=0.0199, for BF and BF-RC, respectively). 
The potential cytotoxic effects of either biofilm supernatants on the MM6 cells, 
were analyzed by measuring the extracellularly released LDH. After 24 hours, no 
differences were found compared to the BF group, but the BF-RC group demonstrated a 
slight yet significant (p<0.025) increase in extracellular LDH release (data not shown). 
Cytokine release in response to biofilm challenge, with engagement or inhibition 
of TREM-1 
To analyse the involvement of TREM-1 in cytokine release by MM6 cells upon biofilm 
challenge, the TREM-1 receptor was either engaged by goat anti-human TREM-1 IgG or 
inhibited by the synthetic LP17 peptide, for over a period of 24 h. The concentrations of 
IL-1β and IL-8 in the culture supernatant were thereafter measured by ELISA. In the 
absence of any modulation of TREM-1, the cells challenged with biofilm supernatants 
showed elevated IL-1β levels, when compared to the control (Fig. 4).  However, the 
increase (1.43-fold) in IL-1β caused by BF was not significant (p=0.08), whereas in the 
BF-RC group IL-1β was significantly (p=0.017) increased by 1.37-fold. Nevertheless, 
when the effects of the two biofilms were compared, there were no significant 
differences between them. 
Further on, when TREM-1 was inhibited by the LP17 peptide, IL-1β levels were 
significantly (p<0.025) reduced in both biofilm groups (1.9-fold and 1.8-fold decrease, BF 
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and BF-RC, respectively), than in the same groups without inhibition of TREM-1 (Fig. 4). 
The same effect was observable in the un-challenged MM6 cell cultures. Still, there was 
no significant difference between the two biofilm groups (p=0.8). 
Moreover, MM6 cells treated with goat anti-human TREM-1 IgG to engage 
TREM-1 activity, and challenged by either biofilm supernatant, demonstrated 
significantly higher levels of IL-1β secretion after 24, compared to MM6 cells that had 
been treated with normal goat IgG isotype control (p<0.02) (1.84-fold increase for BF 
and 1.4-fold for BF-RC, respectively) (Fig. 5). A similar increase in IL-1β production of 
the magnitude of 1.9-fold could be observed in MM6 cells engaged by goat anti-human 
TREM-1 IgG, in the absence of any biofilm challenge. However it was marginally non-
significant (p=0.051). 
In the absence of any TREM-1 modulation, BF-RC caused significantly 
(p=0.0021) higher secretion of IL-8 than the control by over 24 h (2.1-fold increase). 
However, IL-8 secretion in response to BF was not significantly different than the control 
(p=0.0983), despite a 1.8-fold increase (Fig. 6). Moreover, no statistically significant 
difference in the IL-8 secretion was detected between the BF and BF-RC groups. 
Inhibition of TREM-1 by LP17 peptide did not affect IL-8 secretion levels after 24 h, 
irrespective of the biofilm challenge (Fig. 6). Engagement of TREM-1 by means of goat 
anti-human TREM-1 IgG did not affect the production of IL-8 (Fig. 7), as this was 
enhanced by both BF and BF-RC compared to the control, irrespective of treatment with 
anti-TREM-1 IgG or isotype matched IgG (p<0.0025). No significant difference was 
observed in IL-8 secretion, between the two biofilm groups. 
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Discussion 
The present study investigated the expression of TREM-1 mRNA in healthy and 
periodontitis-affected human gingival tissue samples, as well as its correlation with site-
specific clinical and microbiological parameters. Furthermore, to approach the 
mechanisms of TREM-1 regulation by periodontal pathogens, human monocytic cells 
were challenged with oral biofilm supernatants and were analyzed for the expression of 
TREM-1 mRNA, sTREM-1 release, as well as the production of IL-1β and IL-8. As 
expected levels of all three “red complex” species, were significantly increased in 
gingival tissue samples from both forms of periodontitis, whereas A. 
actinomycetemcomitans was only found to be significantly elevated in aggressive 
periodontitis. These microbiological findings are in concordance with the known 
occurrence of periodontal pathogens in the two types of periodontitis, with A. 
actinomycetemcomitans being most abundant in aggressive cases [3, 4]. 
TREM-1 mRNA expression in gingival tissue was significantly increased in 
chronic and in aggressive periodontitis when compared to health, but the difference 
between the two forms of periodontitis was not statistically significant. Furthermore 
TREM-1 mRNA expression was positively correlated with all three “red complex” 
species, but not A. actinomycetemcomitans, as well as bleeding on probing, a clinical 
marker of inflammation. The role of TREM-1 is thought to be the propagation of 
inflammatory response, particularly following challenge of monocytes and neutrophils 
with bacteria or their released products [10, 11, 28]. Hence, the observed correlation of 
TREM-1 expression with the increased levels of three major periodontal pathogens, is 
well in line with the inflammatory nature of periodontitis. Other clinical parameters were 
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not significantly correlated with TREM-1 mRNA expression, possibly due to that these 
are associated with the severity, or past progression, of the disease, rather than active 
inflammation. These findings at the mRNA level are in agreement with previous 
observations showing that periodontitis-affected sites exhibit increased amounts of 
sTREM-1 protein in gingival cervical fluid (GCF). In a recent study in GCF, it was also 
shown that sTREM-1 levels significantly correlated to parameters of clinical severity of 
the disease [22], which was not the case in the present study investigating mRNA 
expression. Nevertheless, in both studies the magnitude of correlations with clinical 
parameters was similar and not too large. The differences in statistical significance could 
well be attributed to that more GCF samples (n=62) were analyzed in this earlier study, 
than were tissue samples (n=45) in the present study. Although the magnitude of 
difference in TREM-1 tissue expression between chronic and aggressive periodontitis 
was greater than what was found earlier in GCF, in neither case did it prove to be 
statistically significant. This may not be surprising, as no solid differences in the 
immunopathology of chronic and aggressive periodontitis have been established [29, 
30]. 
Beyond these clinical findings in TREM-1 tissue expression in periodontal health 
and disease, the present study employed also an in vitro model, in an attempt to 
investigate further the mechanisms of TREM-1 regulation in response to oral biofilms. 
The MM6 monocytic cell line was challenged with culture supernatants of an in vitro-
generated biofilm that consisted of species representative of the subgingival bacterial 
flora. While no sTREM-1 could be detected in the control group, challenge of the cells 
with a 10-species variant including the “red complex” species, resulted in a significant 
release sTREM-1 protein in the culture after 3 h. The seven species biofilm variant 
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lacking the “red complex” caused a less pronounced increase of sTREM-1. In terms of 
mRNA expression levels, both biofilms enhanced TREM-1 expression compared to the 
control, while the difference between the two biofilm groups was also significant, with the 
lack of the “red complex” causing a weaker effect. The increase in TREM-1 suggests 
that the bacterial products of the “red complex” species may have the ability activate the 
TREM-1 pathway more so than other oral microbes. This could result in increased 
inflammation, which suggests a possible mechanism of exerting their high virulence 
properties. These findings may well be in line with previous observations, demonstrating 
that live P. gingivalis stimulates TREM-1 mRNA expression in MM6 cells, concomitantly 
with an enhanced secretion of sTREM-1 in the culture medium [19], an effect that can be 
diminished by administration of doxycycline [31]. The process by which sTREM-1 is 
shed and secreted from the cell surface may involve bacterial proteinases, especially the 
P. gingivalis gingipains, as previously reported [20]. This could further explain the ability 
of the “red complex” species to enhance sTREM-1 secretion in the present experimental 
model, with consequences in the induction of periodontal inflammation. 
The production of the pro-inflammatory cytokines IL-8 and IL-1β was also 
investigated in the present in vitro experimental system. Although there was a tendency 
for increased IL-1β and IL-8 secretion in response to either biofilm, a significant 
enhancement was only confirmed when the “red complex” was absent, and there was no 
difference between the two biofilm groups. Hence, differences in the TREM-1 regulatory 
effects between the two biofilms did not directly match cytokine production. This could 
be either because of the existence of additional pathways other than TREM-1 
responsible for cytokine regulation, or because of the high proteolytic activity of the “red 
complex” species that can degrade pro-inflammatory cytokines, once secreted. Indeed, 
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when the “red complex” is present in the biofilm, it can  cause reduction of IL-8 secretion 
by gingival epithelial cells [20]. 
When TREM-1 was engaged by anti-TREM-1, IL-1β was increased in all 
experimental groups, including the unchallenged controls. It has previously been 
reported that in co-culture of P. gingivalis with MM6 cells, TREM-1 engagement 
increases IL-1β production [19]. Collectively, these results suggest that the TREM-1 
signaling pathway is indeed involved in the increased IL-1β secretion in response to live 
P. gingivalis, as well as bacterial products from biofilms. Accordingly, when TREM-1 was 
inhibited by the LP17 peptide, the opposite effect could be observed, also in line with 
earlier reporting [19]. These findings corroborate further the role of TREM-1 in the 
production of IL-1β upon bacterial challenge. 
On the contrary, inhibition or engagement of TREM-1 did not affect IL-8 secretion, 
even though this was increased upon bacterial challenge by both biofilm supernatants. 
This is in contrast to the previous study demonstrating that IL-8 secretion in MM6 
challenged with P. gingivalis is modulated by TREM-1 in the same manner [20]. It is 
unclear why this discrepancy occurs between live P. gingivalis and subgingival biofilm 
supernatants. Potentially, TREM-1 may only modulate IL-8 production in response to live 
bacteria, whereas secreted bacterial products may be insufficient to induce this effect. 
Alternatively, the regulation of TREM-1 may be more complex in response to a mix of 
bacterial stimulants, where their different virulence properties may out-compete each 
other, resulting in the ablation of the effect. Further research is necessary to identify the 
TREM-1 ligand and the downstream mechanisms behind the selective involvement of 
TREM-1 in cytokine regulation. 
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In conclusion, the present study demonstrates that TREM-1 expression is 
increased in the gingival tissue affected by aggressive and chronic periodontitis, and is 
associated with the bacterially-induced inflammation of the tissue. Furthermore, 
mechanistically it shows that a periodontitis-associated biofilm can enhance TREM-1 in 
monocytes, which may in turn selectively enhance IL-1β secretion by the cells. The 
three “red complex” species have a particular role in the magnitude of these effects. 
TREM-1 exerts a role in the inflammation associated with periodontal disease, most 
likely via the propagation of pro-inflammatory cytokine production by cells of the immune 
system present in the tissues. These findings suggest that inhibition of TREM-1 may be 
a viable point of vantage to consider in future anti-inflammatory periodontal therapy, as 
has been shown in the case of doxycycline [31]. 
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Tables 
Table 1 Primer Sequences for Bacterial Quantification by qPCR 
Primer Sequence 
T. forsythia forward CGATGATACGCGAGGAACCTTACCC 
T. forsythia reverse CCGAAGGGAAGAAAGCTCTCACTCT 
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T. denticola forward TAAGGGACAGCTTGCTCACCCCTA 
T. denticola reverse CACCCACGCGTTACTCACCAGTC 
P. gingivalis forward GCGAGAGCCTGAACCAGCCA 
P. gingivalis reverse ACTCGTATCGCCCGTTATTCCCGTA 
A. actinomycetemcomitans forward GTGGGGAGCAAACAGGATTAG 
A. actinomycetemcomitans reverse CCTAAGGCACAAACCCATCTC 
Table 2 Full mouth clinical periodontal measurements of the study groups. 
Clinical 
parameters 
Controls (healthy) 
(n=15) 
Chronic 
Periodontitis 
(n=15) 
Aggressive 
Periodontitis 
(n=15) 
Age (years) 36.2 ± 13.25 45.2 ± 7.91 * 34.93 ± 5.85 
PD (mm) 1.91 ± 0.21 4.95 ± 0.4 *** 5.55 ± 0.79 *** 
CAL (mm) 1.94 ± 0.22 5.69 ± 0.75 *** 6.41 ± 1.05 *** 
PI 0.78 ± 0.38 2.42 ± 0.5 *** 2.06 ± 0.5 *** 
BOP (%) 25.6 ± 15 78.3 ± 49.5 *** 60 ± 22.9 *** 
Values represent means ± standard deviations. Significance of differences compared to 
the control group (***p< 0.0001, **p< 0.01, *p< 0.05) 
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Table 3 Site specific clinical measurements 
Measurements Control (healthy 
site) (n=15) 
Chronic 
Periodontitis 
(n=15) 
Generalized 
Aggressive 
Periodontitis 
(n=15) 
PD (mm)  1.27 ± 0.45 6.8 ± 1.65 *** 7.07 ± 1.48 *** 
CAL (mm) 1.27 ± 0.45 8.4 ± 2.35 *** 8.07 ± 1.79 *** 
PI 0.07 ± 0.25 2.53 ± 0.64 *** 2.07 ± 0.79 *** 
BOP (%) 0 ± 0 93.3 ± 25.8 *** 86.7 ± 35.2 *** 
Values represent means ± standard deviations. Significance of differences compared to 
the control group (***p< 0.0001, **p< 0.01, *p< 0.05) 
 
Table 4 Correlations between site-specific clinical measurements, microbiological 
findings and relative tissue TREM-1 mRNA expression. 
Measurements Spearman’s rho correlation coefficient (n=45) 
PD (mm) 0.273 (p=0.069) 
CAL (mm) 0.179 (p=0.239) 
PI 0.229 (p=0.130) 
BOP 0.363* (p=0.014) 
P. gingivalis 0.495** (p=0.001) 
T. denticola 0.471** (p=0.001) 
T. forsythia 0.438** (p=0.003) 
A. actinomycetemcomitans 0.206 (p=0.174) 
Significance of correlation: *p < 0.05, **p < 0.005. 
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Figure Legends 
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Figure 1 (A) Site specific counts of P. gingivalis, (B) T. forsythia, (C) T. denticola, and  
(D) A. actinomycetemcomitans per mg of tissue sample. The horizontal line depicts the 
median value (*** p< 0.0001 and ** p< 0.01). 
 
 
Figure 2: Relative expression of TREM-1 mRNA in gingival tissue samples from healthy 
sites as well as sites affected by chronic and aggressive periodontitis. The horizontal line 
depicts the median value (*p<0.05). 
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Figure 3 (A) sTREM-1 secretion by MM6 cells after 3h of challenge with 10 species 
biofilm supernatant, as well as supernatants of biofilms in which the three red complex 
species were excluded from the composition (*p=0.0067, ‡p=0.0023). (B) Relative 
TREM-1 mRNA expression after 3h of challenge (*p=0.0256, ‡p=0.0033, #p=0.0199). 
Control: no biofilm, BF: 10 species biofilm, -RC: 7 species biofilm excluding the “red 
complex” 
 
Figure 4: Effect of inhibition of TREM-1 by the LP17 peptide on IL-1β production 
(*p=0.0006, ‡p=0.0218, #p=0.0024). Control: no biofilm, BF: 10 species biofilm, -RC:  7 
species biofilm lacking “red complex” species. 
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Figure 5: Effect of engagement of TREM-1 by anti-TREM-1 antibody on IL-1β 
production (*p=0.0098, p=0.0193). C T-1 IgG: Control, goat anti-human TREM-1 IgG. BF 
T-1 IgG: 10 species biofilm, goat anti-human TREM-1 IgG. -RC T-1 IgG: Excluding red 
complex, goat anti-human TREM-1 IgG. C G IgG: Control, normal goat IgG. BF G IgG: 
10 species biofilm, normal goat IgG, -RC G IgG: Excluding red complex, normal goat 
IgG. 
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Figure 6: Effect of inhibition of TREM-1 by the LP17 peptide on IL-8 production. C: 
control (no biofilm), BF: 10 species biofilm, -RC: 7 species biofilm lacking “red complex” 
species. 
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Figure 7: Effect of engagement of TREM-1 by anti-TREM-1 antibody on IL-8 production. 
C T-1 IgG: Control, goat anti-human TREM-1 IgG. BF T-1 IgG: 10 species biofilm, goat 
anti-human TREM-1 IgG. -RC T-1 IgG: Excluding red complex, goat anti-human TREM-
1 IgG. C G IgG: Control, normal goat IgG. BF G IgG: 10 species biofilm, normal goat IgG 
-RC G IgG: Excluding red complex, normal goat IgG. 
